Zavzpret (Zavegepant) for Migraine

Overview
Zavzpret is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura in adults. It is not indicated for the preventive treatment of migraine. Zavzpret is also known by its drug name, zavegepant.

Zavzpret belongs to the class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. It is thought to work by blocking the activity of CGRP, a molecule involved in migraine attacks, thereby reducing the pain and other symptoms associated with migraine.

How do I take it?
Zavzpret is administered as a nasal spray, given as a single spray in one nostril, as needed. The maximum dose in a 24-hour period is one spray. Prescribing information recommends against treating more than eight migraine attacks in a 30-day period with Zavzpret. This medication should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Zavzpret include taste disorders, nausea, nasal discomfort, and vomiting. 

Rare but serious side effects may include hypersensitivity reactions, such as facial swelling and urticaria (hives).

For more information about this treatment, visit:

Highlights of Prescribing Information: Zavzpret (Zavagepent) Nasal Spray — U.S. Food and Drug Administration